EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Sponsor
Insel Gruppe AG, University Hospital Bern
Study ID
NCT07434713
Status
Recruiting
Apply to this trial

Conditions

  • Age-Related Macular Degeneration (AMD)

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration. Retinal fluid dynamics assessed by optical coherence tomography and changes in best-corrected visual acuity two months after baseline are analyzed to characterize early treatment outcomes.

Key Dates

Start date
Jul 14, 2025
Status verified
Feb 2026
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: all study participants

Primary Outcome Measure

Fluid dynamics on OCT scans during the early treatment phase of macular degeneration with Aflibercept 8mg. [ Time Frame: Each participant is followed up for 2 months after their treatment with aflibercept 8mg. From study enrollment and the 1st injection, over weekly check ups until the 2nd injection, completed with a last visit and the 3rd and last injection. ]

Central Contacts

Related Studies